FZata, Inc. is usefully understood as an antibody technology company organized around development of antibody-based therapeutic and preventive medicines utilizing the power of human immunity of antibodies for applications against diseases. Activating the Human Protective Antibody Platform, the effort is to develop antibody from human B cells Pure human antibody from naturally selected B cells for natural targets Enable high-throughput screening for functional antibody High success rate and highly efficient Proprietary, state-of-the-art & versatile Successfully applied in developing antibodies against HIV, C. difficile & Hepatitis B virus. The firm's first-in-class Bioengineered Probiotic Yeast Medicines (BioPYM) platform is a novel oral administration modality for biologics. Fzata's vision is to replace needle administration of biologics for sufferers of gastrointestinal disorders with a capsule.
